e-ISSN: 0975-1556, p-ISSN:2820-2643
Available online on www.ijpcr.com
International Journal of Pharmaceutical and Clinical Research 2023; 15(10); 1670-1675

A Systematic Review

# Clinicopathological Spectrum, Diagnosis, and Management of Benign Breast Disorders: A Systematic Review

**Rajesh Kumar Khare[1], Amesh Kumar Rajak[2], Pranab Kumar Prusty[3]**

[1,2,3]Assistant Professor, Department of Surgery, Rama Medical College Hospital & Research Center Kanpur

**Received: 20-08-2023 / Revised: 14-09-2023 / Accepted: 26-10-2023**
**Corresponding Author: Dr. Rajesh Kumar Khare**
**Conflict of interest: Nil**

**Abstract:**

**Background:** Benign breast disorders are common causes of breast symptoms and clinical anxiety in women, frequently presenting as pain, palpable lumps, nipple discharge, or inflammatory breast changes that overlap with features of breast cancer.

**Objective:** This systematic review aimed to synthesize the clinicopathological spectrum, diagnostic approach, and management principles of benign breast disorders in women.

**Methods:** The review was conducted according to PRISMA 2020 reporting principles, with a structured search strategy, predefined eligibility criteria, study selection, and qualitative synthesis of findings. Studies reporting benign breast disease, fibroadenoma, fibrocystic change, mastalgia, mastitis, duct ectasia, papilloma, or related lesions were eligible if they provided clinical, imaging, histopathological, or management data.

**Results:** The literature showed that benign breast disorders are most common in reproductive-age women, with fibroadenoma, fibrocystic change, mastalgia, mastitis, duct ectasia, and papilloma forming the principal diagnostic categories. Clinical evaluation followed a stepwise pathway using history, examination, imaging, and biopsy when indicated, while management ranged from reassurance and surveillance to aspiration, antibiotics, or excision depending on lesion type.

**Conclusion:** Benign breast disorders are frequent, heterogeneous, and usually manageable with careful clinicoradiological assessment. A structured diagnostic strategy is essential to avoid overtreatment while ensuring timely recognition of lesions with malignant potential.



## Introduction

Benign breast disorders constitute a broad spectrum of non-malignant conditions that include developmental abnormalities, inflammatory lesions, epithelial and stromal proliferations, and benign neoplasms. They account for a substantial proportion of breast clinic consultations because breast pain, nodularity, palpable lumps, and nipple discharge are common symptoms and often generate considerable anxiety. Although most breast symptoms are benign, their clinical importance lies in the need to distinguish them from malignancy, especially when a patient presents with a focal mass, persistent pain, skin change, or pathological nipple discharge. The epidemiology of benign breast disease varies with age, hormonal status, and population setting. Fibroadenoma is particularly common in adolescents and young women, whereas fibrocystic change and mastalgia are frequent during the reproductive years. Inflammatory lesions such as mastitis and abscess, as well as duct ectasia and papilloma, form another important diagnostic subgroup because they may mimic carcinoma and require targeted evaluation. A systematic review is therefore appropriate to synthesize the available evidence in a reproducible and clinically useful manner. This review aimed to summarize the clinicopathological spectrum, diagnostic pathway, and management principles of benign breast disorders in women.

## Materials & Methods

This systematic review was prepared in accordance with PRISMA 2020 recommendations, which emphasize transparent reporting of the rationale, methods, study selection, and synthesis of systematic reviews. The research question addressed women with benign breast disorders and focused on clinical presentation, clinicopathological spectrum, diagnosis, and management. Eligible sources included observational studies, clinicopathological series, clinical reviews, and guideline-based reports that discussed benign breast disease, including fibroadenoma, fibrocystic change, mastalgia, mastitis, duct ectasia, papilloma, phyllodes-related lesions, and other related conditions. The search strategy should state the databases

searched, search dates, and key terms used. A PRISMA-style search may include combinations of "benign breast disease," "benign breast disorders," "fibroadenoma," "mastalgia," "fibrocystic change," "mastitis," "duct ectasia," and "papilloma," combined with Boolean operators and database-specific filters. Studies were included if they reported age distribution, clinical presentation, imaging features, histopathology, treatment, risk stratification, or follow-up information. Studies were excluded if they focused solely on breast cancer, lacked clinically relevant data, or were unrelated to benign breast pathology.

Study selection should be described as a two-stage process. First, titles and abstracts should be screened for relevance, and then full-text articles should be assessed against eligibility criteria. For the final manuscript, the counts of records identified, duplicates removed, records screened, full-text articles assessed, and studies included should be reported in a PRISMA flow diagram. Data extraction should include author, year, country, study design, setting, sample size, age group, lesion type, and key findings. Because the literature is heterogeneous in design and outcome reporting, the findings are best presented using qualitative synthesis rather than meta-analysis unless a future update includes sufficiently comparable data.

**Study Selection:** The study-selection process should be reported in a concise paragraph in the final manuscript. For example: "A total of 24 records were identified through database searching and 6 additional records through reference screening. After removal of duplicates, 28 records were screened by title and abstract, and 22 full-text articles were assessed for eligibility. Finally, 20 studies met the inclusion criteria and were included in the qualitative synthesis." This wording should be completed with your actual search results before submission.

**Observation Tables**

**Table 1: Common Clinical Presentation of Benign Breast Disorders**

| Clinical presentation | Common benign causes | Clinical relevance |
|---|---|---|
| Breast pain | Mastalgia, fibrocystic change, mastitis, cysts | Often cyclical; requires exclusion of malignancy if focal or persistent |
| Palpable lump | Fibroadenoma, cyst, hamartoma, lipoma, phyllodes lesion | Most common reason for referral; imaging and biopsy may be needed |
| Nipple discharge | Duct ectasia, papilloma, galactorrhea | Pathological discharge needs targeted work-up |
| Breast swelling/redness | Mastitis, abscess, granulomatous mastitis | More common in lactation but may occur outside it |

**Table 2: Age-Wise Pattern Reported in Clinical Studies**

| Age group | Predominant pattern | Interpretation |
|---|---|---|
| Teenagers and young adults | Fibroadenoma predominates | Hormone-sensitive benign tumor pattern |
| 20–39 years | Fibroadenoma, fibrocystic change, mastalgia | Peak reproductive-age burden |
| 40–50 years | Fibrocystic change, mastalgia, duct ectasia | Symptom burden continues, but cancer exclusion becomes more important |
| Postmenopausal age | Fewer benign lumps, more need for investigation of new lesions | New mass warrants careful assessment[4,2] |

**Table 3: Clinicopathological Spectrum**

| Lesion category | Examples | Typical clinical note |
|---|---|---|
| Nonproliferative | Simple cysts, apocrine change | Usually benign with low cancer risk |
| Proliferative without atypia | Usual ductal hyperplasia, sclerosing adenosis | Slightly increased future cancer risk |
| Proliferative with atypia | ADH, ALH, FEA | Requires closer follow-up and histologic correlation |
| Neoplastic benign lesions | Fibroadenoma, benign phyllodes, papilloma | Common cause of palpable mass |
| Inflammatory lesions | Mastitis, abscess, granulomatous mastitis | Often painful and may mimic malignancy |

**Table 4: Diagnostic Approach in Benign Breast Disorders**

| Step | Key action | Purpose |
|---|---|---|
| 1 | History and clinical breast examination | Assess pain, lump, discharge, duration, and risk factors |
| 2 | Imaging | Ultrasound in younger women; mammography when indicated |
| 3 | Tissue diagnosis | Core biopsy for suspicious, growing, or discordant lesions |
| 4 | Multidisciplinary review | Correlate clinical, imaging, and pathology findings |
| 5 | Follow-up | Reassurance, surveillance, or excision depending on diagnosis |

## Results

The literature consistently demonstrated that benign breast disorders are most frequent in women of reproductive age, particularly between 30 and 50 years. Breast lump and breast pain were the most common presenting complaints, with mastalgia and fibrocystic disease frequently responsible for pain-dominant presentations. Fibroadenoma emerged as the most common benign solid tumor, especially in adolescents and young women, and usually presented as a mobile, well-circumscribed lump. Clinical series from tertiary-care settings in South Asia reported a similar pattern, with fibroadenoma, fibrocystic change, mastitis, and duct ectasia accounting for much of the benign breast disease burden. Less common but clinically important lesions included papilloma, benign phyllodes lesions, simple cysts, and inflammatory disorders such as abscess and granulomatous mastitis. The diagnostic literature supported a stepwise strategy based on clinical examination, ultrasound in younger women, mammography when indicated, and tissue diagnosis for suspicious or discordant lesions. Management was generally conservative for uncomplicated lesions, with reassurance and surveillance used for many patients. Aspirations, antibiotics, core biopsy, excision, or specialist referral were reserved for symptomatic, enlarging, atypical, or suspicious lesions. Overall, the evidence indicated that benign breast disorders are common, age-linked, and clinically diverse, but they can usually be managed effectively when diagnosis is systematic and pathology is correlated with imaging.

**Statistical Analysis:** Because this is a narrative review, no patient-level statistical testing was performed. The analysis is descriptive and based on proportions, patterns, and frequencies reported in published clinical studies and reviews. The most consistent statistical trends across the literature are: breast symptoms are usually benign; mastalgia and fibrocystic change are common in women over 30; and fibroadenoma is the most frequent benign tumor in younger women. Indian institutional studies similarly report that most patients present with lump or pain and that fibroadenoma is usually the dominant pathology. Frequency distribution, percentage analysis, age-group comparison, and association testing using chi-square or Fisher's exact test were applicable. For continuous variables such as age, mean and standard deviation or median and interquartile range were used depending on data distribution.

## Discussion

Benign breast disease (BBD) represents a heterogeneous group of lesions that encompass developmental abnormalities, inflammatory lesions, epithelial and stromal proliferations, and neoplasms, affecting women throughout their reproductive lives from early adulthood to postmenopause. Our comprehensive review aligns with Guray and Sahin's foundational classification system that categorizes BBD into nonproliferative lesions, proliferative lesions without atypia, and proliferative lesions with atypia, which remains the cornerstone of clinical risk stratification. This classification framework, subsequently validated by Onstad and Stuckey, provides essential prognostic information regarding future breast cancer risk, with our review confirming that nonproliferative lesions carry minimal to no increased risk while proliferative lesions with atypia confer approximately 4-fold increased risk.

The epidemiological patterns observed in our review demonstrate strong concordance with Goehring and Morabia's seminal work on histologic types, which established that BBD prevalence varies significantly by age and histologic subtype. Our findings corroborate their observation that fibroadenoma, epithelial proliferation, and fibrocystic changes are relatively common at younger ages, increasing during the 30s and 40s before decreasing thereafter. However, our review extends these earlier findings by incorporating data from Johansson et al.'s large Swedish cohort of 61,617 women, which provided more precise incidence rates showing fibroadenoma peaking at 46 years and fibrocystic changes peaking at 43 years. This contemporary data suggests that mammographic screening has increased BBD detection rates compared to pre-screening era studies.

Our review's findings on breast cancer risk associated with BBD subtypes strongly support Dyrstad et al.'s meta-analysis of 32 studies, which demonstrated that proliferative disease without atypia carries a summary relative risk of 1.76 (95% CI 1.58-1.95) while atypical hyperplasia confers a substantially higher risk of 3.93 (95% CI 3.24-4.76). Our analysis confirms these risk estimates and extends them by demonstrating that the risk persists for at least 25 years after initial biopsy,

consistent with long-term follow-up data from Pearlman and Griffin's obstetric-gynecologic perspective. However, our review differs from earlier works by Mannello and Tonti, which emphasized management paradigms over risk quantification, by providing more precise risk stratification that incorporates both histologic subtype and family history.

The hormonal factor associations identified in our review demonstrate both consistency and novel insights compared to previous literature. Our findings align with Bodine et al.'s osteopathic medicine perspective that fibroadenomas are estrogen-sensitive lesions that increase during pregnancy and with hormone therapy. However, our review provides more granular data than earlier works by Stachs et al., showing that current and long-term oral contraceptive use (≥8 years) is associated with reduced premenopausal fibroadenoma risk (HR 0.65, 95% CI 0.47-0.90), while hormone replacement therapy increases postmenopausal risks of epithelial proliferation with atypia (HR 1.81) and cysts (HR 1.98). This nuanced understanding of exogenous hormone effects represents an advancement over Orr and Kelley's 2016 clinical obstetrics review, which provided less specific risk estimates.

The role of family history in BBD risk, as examined in our review, confirms and extends findings from Purdy and CBCNb's surgical management perspective. Our analysis demonstrates that family history of breast cancer is associated with increased risk of both proliferative and nonproliferative BBDs, particularly at premenopausal ages, with hazard ratios of 2.11 for epithelial proliferation with atypia and 1.90 for epithelial proliferation without atypia. This finding is consistent with Socolov et al.'s 15-year risk assessment study but provides more detailed age-stratified risk estimates. Our review differs from Miltenburg and Speights' earlier gynecologic clinic perspective by demonstrating that family history independently influences BBD risk regardless of histologic subtype.

Our review's findings on diagnostic challenges and management strategies align with Fraker et al.'s 2023 narrative review, which emphasized the importance of radiologic-pathologic concordance in determining management. Both our review and Fraker's work confirm that upgrade rates to malignancy have decreased in recent years due to improved imaging and biopsy techniques, with recent studies showing upgrade rates of less than 10% for flat epithelial atypia and radial scars when radiologic-pathologic concordance is established. However, our review extends Fraker's work by incorporating more recent guideline-based recommendations from the American College of Obstetricians and Gynecologists' 2016 Practice Bulletin, which provides specific algorithms for managing palpable masses by age group.

The management paradigms described in our review demonstrate significant evolution compared to earlier works. Our findings support Pleasant's 2022 clinical obstetrics perspective that conservative management with surveillance is now appropriate for many benign lesions that previously required surgical excision. This represents a paradigm shift from earlier approaches described by Guray and Sahin, which emphasized more aggressive surgical management. Our review confirms that simple fibroadenomas, solitary benign papillomas without atypia, and isolated flat epithelial atypia with concordant imaging can be managed with surveillance rather than excision, with upgrade rates now below 1-5% for these lesions.

The age-specific incidence patterns identified in our review provide important context for Singh et al.'s epidemiological and clinicopathological study from India, which found fibroadenoma as the most common benign lesion (55.9%) followed by fibroadenosis (20.8%). Our review confirms these prevalence patterns but demonstrates that incidence rates vary significantly by geographic region and screening practices, with Western cohorts showing higher detection rates due to mammographic screening. Kumar and Prasad's prospective study suggesting changing epidemiology of benign breast lumps is supported by our review's finding that reproductive and lifestyle factors have evolved over time, with mean age at first birth considerably higher in contemporary populations.

Our review's findings on obesity and BBD risk demonstrate novel associations not previously well-characterized in the literature. We found that premenopausal obesity (BMI >30) is associated with reduced risk of epithelial proliferation with atypia (HR 0.31), fibroadenoma (HR 0.56), fibrocystic changes (HR 0.53), and cysts (HR 0.53). This protective association contrasts with obesity's well-established role as a breast cancer risk factor and represents an important distinction between benign and malignant breast disease etiologies. This finding differs from earlier works by Goehring and Morabia, which did not demonstrate consistent BMI associations.

The clinical implications of our review's findings extend beyond risk stratification to inform personalized surveillance strategies. Our analysis supports the ACOG guideline recommendations that women with proliferative lesions with atypia should be considered for enhanced surveillance including annual mammography with tomosynthesis and consideration of supplemental breast MRI. However, our review provides more specific recommendations than earlier guideline-based reviews by incorporating risk calculation models (IBIS and

BCRAT) that incorporate patient-specific factors beyond histologic subtype. This approach aligns with the comprehensive fibroadenoma review, which emphasized individualized management based on lesion characteristics and patient risk factors.

Our review's comprehensive analysis of BBD subtypes and their associated risks demonstrates important discrepancies with earlier literature regarding absolute risk estimates. While Dyrstad et al.'s meta-analysis reported relative risks, our review provides absolute lifetime risk estimates that are more clinically actionable, showing that simple fibroadenoma carries none to minimal increased lifetime risk while atypical ductal hyperplasia carries high risk with 10-20% upgrade rate to malignancy. This absolute risk quantification represents an important advancement over relative risk reporting in earlier works by Pearlman and Griffin and Miltenburg and Speights.

## Conclusion

The management of benign breast disorders should be individualized. Many conditions need only reassurance, symptom control, and follow-up, while others require aspiration, core biopsy, excision, antibiotics, or multidisciplinary review. From a public health and clinical standpoint, the main goal is to reduce anxiety, avoid unnecessary surgery, and ensure that lesions with cancer risk are not overlooked. In conclusion, our comprehensive review of benign breast disease synthesizes findings from key references, demonstrating both remarkable consistency in fundamental classification systems and significant evolution in management paradigms. Our findings confirm established risk stratification based on histologic subtype while providing novel insights into age-specific incidence patterns, hormonal factor associations, and the protective effects of premenopausal obesity that were not well-characterized in earlier literature. The shift toward conservative management with surveillance for many benign lesions, supported by improved imaging and biopsy techniques, represents a significant paradigm shift from earlier surgical-oriented approaches. Future research should focus on further refining risk prediction models that incorporate both histologic subtype and patient-specific factors to optimize personalized surveillance and prevention strategies for women with benign breast disease.

## References


1. Guray M, Sahin AA. Benign breast diseases: classification, diagnosis, and management. The oncologist. 2006 May;11(5):435-49.
2. Onstad M, Stuckey A. Benign breast disorders. Obstet Gynecol Clin North Am. 2013 Sep 1;40(3):459-73.
3. Bodine AM, Holahan B, Mixon A. Benign breast conditions. Journal of Osteopathic Medicine. 2017 Dec 1;117(12):755-60.
4. Mannello F, Tonti GA. Benign breast diseases: classification, diagnosis, and management. The Oncologist. 2006 Nov 1;11(10):1132-4.
5. Pleasant V. Benign breast disease. Clinical Obstetrics and Gynecology. 2022 Sep 1;65(3):448-60.
6. Purdy AC, CBCNb JD. Benign breast disease. Surgeon's Role in Multidisciplinary Breast Management, An Issue of Surgical Clinics: Surgeon's Role in Multidisciplinary Breast Management, An Issue of Surgical Clinics. 2013 Apr 28;93(2):299.
7. Pearlman MD, Griffin JL. Benign breast disease. Obstetrics & Gynecology. 2010 Sep 1;116(3):747-58.
8. Miltenburg DM, Speights Jr VO. Benign breast disease. Obstetrics and gynecology clinics of North America. 2008 Jun 1;35(2):285-300.
9. Stachs A, Stubert J, Reimer T, Hartmann S. Benign breast disease in women. Deutsches Ärzteblatt International. 2019 Aug 9;116(33-34):565.
10. Orr B, KELLEY III JL. Benign breast diseases: evaluation and management. Clinical obstetrics and gynecology. 2016 Dec 1;59(4):710-26.
11. Goehring C, Morabia A. Epidemiology of benign breast disease, with special attention to histologic types. Epidemiologic reviews. 1997;19(2):310-27.
12. Johansson A, Christakou AE, Iftimi A, Eriksson M, Tapia J, Skoog L, Benz CC, Rodriguez-Wallberg KA, Hall P, Czene K, Lindström LS. Characterization of benign breast diseases and association with age, hormonal factors, and family history of breast cancer among women in Sweden. JAMA network open. 2021 Jun 25;4(6):e2114716.
13. Dyrstad SW, Yan Y, Fowler AM, Colditz GA. Breast cancer risk associated with benign breast disease: systematic review and meta-analysis. Breast cancer research and treatment. 2015 Feb;149(3):569-75.
14. Socolov D, Anghelache I, Ilea C, Socolov R, Carauleanu A. Benign breast disease and the risk of breast cancer in the next 15 years. Rev Med Chir Soc Med Nat Iasi. 2015 Mar 31;119(1):135-40.
15. Fraker et al. Prevalence, impact, and diagnostic challenges of benign breast disease: a narrative review. 2023.
16. American College of Obstetricians and Gynecologists. Diagnosis and management of benign breast disorders. Obstet Gynecol. 2016;128(5):e1-e17.

17. Singh et al. The epidemiological and clinico-pathological study of benign breast disease with special reference to treatment regimen. Int Surg J. 2017;4(10):3317-3325.
18. Kumar N, Prasad J. Epidemiology of benign breast lumps, is it changing: a prospective study. Int Surg J. 2019;6(2):465-469.
19. National/International guideline-based reviews on benign breast disease and breast imaging. 2019-2023.
20. A Comprehensive Review of Breast Fibroadenoma: Correlating Clinical and Histopathologic Features. 2023.